
ONC-392
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Loading color scheme
From novel biology to clinical stage products.
Best-in-class and first-in-class immunotherapy products targeting cancer evasion of adaptive and innate immunity.
Our team brings success from biotech pharma, and academia to OncoC4.
Novel antibodies selectively abrogate immune evasion in tumor microenvironment but preserve immune checkpoint against adverse events.
Targeting cancer cells through chimeric antigen receptors T cells (ONC-782), bi-specific antibodies (ONC-783) and antibody-drug conjugates (ONC-784).
OncoC4 has a pipeline of best-in-class and first-in-class immunotherapy products that are moving through preclinical testing.
Developing unique drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
Scientific discoveries drive explosive immunotherapy.
A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway April 25, 2022, Rockville, Maryland. OncoC4, Inc., a clinical stage biopharma company developing novel immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ONC-392, the Company’s next-gen…
ROCKVILLE, Md., Mar. 31, 2022 - The CEO Publication, a unique digital platform featuring the industry experts who have created ripples across various areas of expertise, has acknowledged Dr. Yang Liu, Chairman, CEO & CSO, OncoC4 — a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and…
ROCKVILLE, Md., Mar. 15, 2022 - OncoC4, Inc. is recognized by Pharma Tech Outlook as one of the "Top 10 Immunotherapy Solutions Providers - 2022".